GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of how much of what we believe about endpoint actually comes from TRIUMPH threads — 45 comments in the full submission. View in context.
2.2k
c/trialwatch·submitted 4 months ago by u/rt_shift_reggie

how much of what we believe about endpoint actually comes from TRIUMPH threads

Readoutbranch of 7 comments

how much of what we believe about endpoint actually comes from TRIUMPH threads. I would rather ask a basic question now than get this wrong quietly for two months. A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point…

Read the full submission and all 45 comments →

This branch

7 comments, started 4 months ago
u/sofia_wikstrom101 points·4 months ago

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

replysharereportpermalink
u/rt_shift_reggieOP38 points·4 months ago·edited

Read a press release and the publication three months apart. The hedging in the second one was substantial.

replysharereportpermalink
u/aurel_mwangi43 points·4 months ago·edited

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

replysharereportpermalink
u/joaquin_trevino13 points·4 months ago

trial populations get support that nobody on this board gets

replysharereportpermalink
u/yara_mensah15 points·4 months ago

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable

replysharereportpermalink
u/heart_rate_bump67 points·4 months ago

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

replysharereportpermalink
u/rt_shift_reggieOP37 points·4 months ago

That is the 68-week readout, not the 72-week one. Different trial, different duration.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →